COSCIENS Biopharma Inc. Key Management Personnel Compensation Shortterm Employee Benefits
COSCIENS Biopharma Inc. (CSCIF) reported Key Management Personnel Compensation Shortterm Employee Benefits of $2.44 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits · last filed 2026-03-25
- COSCIENS Biopharma Inc. key management personnel compensation shortterm employee benefits for the quarter ending 2022-03-31 was $355.00K, a 62.10% increase year-over-year.
- COSCIENS Biopharma Inc. key management personnel compensation shortterm employee benefits for the quarter ending 2021-12-31 was $678.00K, a 3.97% decline year-over-year.
- COSCIENS Biopharma Inc. key management personnel compensation shortterm employee benefits for the quarter ending 2021-09-30 was $350.00K, a 0.28% decline year-over-year.
- COSCIENS Biopharma Inc. key management personnel compensation shortterm employee benefits for the quarter ending 2021-06-30 was $399.00K.
| Period end | Key Management Personnel Compensation Shortterm Employee Benefits 3 month | Key Management Personnel Compensation Shortterm Employee Benefits 6 month | Key Management Personnel Compensation Shortterm Employee Benefits 9 month | Key Management Personnel Compensation Shortterm Employee Benefits 12 month | Key Management Personnel Compensation Shortterm Employee Benefits 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $2.44M 20-F · filed 2026-03-25 | ||||
| 2024-12-31 | $1.59M 20-F · filed 2026-03-25 | ||||
| 2023-12-31 | $1.34M 20-F · filed 2026-03-25 | $2.02M 20-F · filed 2024-03-27 | |||
| 2022-12-31 | $971.00K 20-F · filed 2025-04-09 | $1.85M 20-F · filed 2023-03-23 | |||
| 2022-03-31 | $355.00K 6-K · filed 2022-05-11 | $1.03M derived: sum of 2 quarters · filed 2024-07-17 | $1.38M derived: sum of 3 quarters · filed 2024-07-17 | $1.78M derived: sum of 4 quarters · filed 2024-07-17 | |
| 2021-12-31 | $678.00K derived: 20-F/A 12 month − 6-K 9 month · filed 2024-07-17 | $1.03M derived: sum of 2 quarters · filed 2024-07-17 | $1.43M derived: sum of 3 quarters · filed 2024-07-17 | $1.65M 20-F/A · filed 2024-07-17 | |
| 2021-09-30 | $350.00K derived: 6-K 9 month − 6-K 6 month · filed 2021-11-04 | $749.00K derived: sum of 2 quarters · filed 2021-11-04 | $968.00K 6-K · filed 2021-11-04 | $1.67M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2021-06-30 | $399.00K derived: 6-K 6 month − 6-K 3 month · filed 2021-08-05 | $618.00K 6-K · filed 2021-08-05 | $1.32M derived: sum of 3 quarters · filed 2024-02-15 | $1.68M derived: sum of 4 quarters · filed 2024-02-15 | |
| 2021-03-31 | $219.00K 6-K · filed 2022-05-11 | $925.00K derived: sum of 2 quarters · filed 2024-02-15 | $1.28M derived: sum of 3 quarters · filed 2024-02-15 | ||
| 2020-12-31 | $706.00K derived: 20-F/A 12 month − 6-K 9 month · filed 2024-02-15 | $1.06M derived: sum of 2 quarters · filed 2024-02-15 | $1.54M 20-F/A · filed 2024-02-15 | ||
| 2020-09-30 | $351.00K derived: 6-K 9 month − 6-K 6 month · filed 2021-11-04 | $834.00K 6-K · filed 2021-11-04 | |||
| 2020-06-30 | $483.00K 6-K · filed 2021-08-05 | ||||
| 2018-12-31 | $2.39M 20-F · filed 2019-04-01 | ||||
| 2017-12-31 | $2.08M 20-F · filed 2019-04-01 | ||||
| 2016-12-31 | $2.43M 20-F · filed 2019-04-01 | ||||
| 2015-12-31 | $2.96M 20-F · filed 2018-03-28 |